Related Experiment Video
Updated: Jan 13, 2026

Quantifying the Modulation of Elastase Enzyme Activity Through Colorimetric Analysis
Published on: January 17, 2025
Low Fecal Elastase-1: A Non-negligible Factor in Functional Dyspepsia Patients
Jiao Liu1, Tian He1, Linglong Ji1
1Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37, Guo Xue Alley, Wu Hou Distinct, Chengdu, 610041, Sichuan, China.
Background And Aim:
Functional dyspepsia (FD) is one of the most prevalent functional gastrointestinal disorders. The occurrence of dyspepsia has been reported to be associated with a deficiency or dysfunction of digestive enzymes. Although the pancreas plays a critical role in secreting digestive enzymes, the relationship between FD and pancreatic exocrine insufficiency (PEI) remains unclear. This study aims to evaluate the prevalence of low Fecal elastase-1 (FE-1) level, a recognized indicator of PEI, in FD patients and explore potential risk factors contributing to this condition.
Methods:
This cross-sectional study enrolled 76 FD patients. The FE-1 level was measured using a commercial ELISA kit. An FE-1 level below 200 μg/g stool was defined as abnormal. Clinical characteristics and gut microbiota composition were compared between FD patients with low FE-1 level (FE-L) and those with normal FE-1 level (FE-N). Logistic regression analysis was used to identify independent risk factors for low FE-1 level in FD patients.
Results:
The prevalence of low FE-1 level among FD patients was 19.7%. Compared to the FE-N group, the FE-L group exhibited higher gastrointestinal symptoms scores, anxiety scores and lower quality of life scores (P < 0.05). Logistic regression analysis revealed that male gender and anxiety state were independent risk factors for low FE-1 level. Gut microbiota analysis demonstrated that Prevotella were significantly enriched, while Bacteroides and Bifidobacterium were decreased in the FE-L group (LDA > 3, P < 0.05).
Conclusions:
The present study suggests that a subset of patients with FD have FE-1 secretion insufficiency and might benefit from pancreatic enzyme supplementation therapy.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Drugs for Treatment of Constipation-Predominant IBS

